Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to $9.1 million.

  • Vanda Pharmaceuticals' Change in Accured Expenses rose 52675.13% to $9.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $15.8 million, marking a year-over-year increase of 82622.95%. This contributed to the annual value of $15.8 million for FY2025, which is 82622.95% up from last year.
  • As of Q4 2025, Vanda Pharmaceuticals' Change in Accured Expenses stood at $9.1 million, which was up 52675.13% from -$10.2 million recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Change in Accured Expenses peaked at $13.4 million during Q1 2022, and registered a low of -$10.8 million during Q1 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' median Change in Accured Expenses value was $735500.0 (recorded in 2022), while the average stood at $1.1 million.
  • In the last 5 years, Vanda Pharmaceuticals' Change in Accured Expenses skyrocketed by 487857.14% in 2022 and then tumbled by 207974.41% in 2025.
  • Vanda Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $2.2 million in 2021, then crashed by 250.32% to -$3.3 million in 2022, then soared by 201.65% to $3.3 million in 2023, then tumbled by 163.85% to -$2.1 million in 2024, then skyrocketed by 526.75% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q4 2025, -$10.2 million for Q3 2025, and $11.3 million during Q2 2025.